We are live on ! Find out more
ALLO icon

Allogene Therapeutics

79 hedge funds and large institutions have $1.67B invested in Allogene Therapeutics in 2018 Q4 according to their latest regulatory filings, with 79 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5,600% more call options, than puts

Call options by funds: $912K | Put options by funds: $16K

51.6% more ownership

Funds ownership: 0%51.6% (+52%)

Holders
79
Holders Change
+79
Holders Change %
% of All Funds
1.76%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
79
Increased
Reduced
Closed
Calls
$912K
Puts
$16K
Net Calls
+$896K
Net Calls Change
+$896K
Name Holding Trade Value Shares
Change
Change in
Stake
CWM
76
Catamount Wealth Management
Connecticut
$7K +$6.11K +230 New
Bessemer Group
77
Bessemer Group
New Jersey
$4K +$3.45K +130 New
CCA
78
Catalyst Capital Advisors
New York
$4K +$4.22K +159 New
Simplex Trading
79
Simplex Trading
Illinois
$3K +$3.11K +117 New

ALLO Hedge Fund Activity: Q4 2018 in Review

79 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2018, worth a combined $1.67B.

Buyers outnumbered sellers: 79 funds opened new ALLO positions and 0 closed out — a net gain of 79 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $615M.

  • 79 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2018, up from 0 in Q3 2018.
  • Funds reported $1.67B of Allogene Therapeutics stock for Q4 2018.
  • 79 funds opened new Allogene Therapeutics positions in Q4 2018 and 0 closed out, a net change of +79 holders.
  • The largest Allogene Therapeutics buyer in Q4 2018 was TPG Group Holdings (SBS) Advisors, an estimated $615M added.

Based on aggregated 13F filings for Q4 2018.